Oncogenic MET as an Effective Therapeutic Target in Non–Small Cell Lung Cancer Resistant to EGFR Inhibitors: The Rise of the Phoenix

Research output: Contribution to journalArticle

Abstract

Anecdotal reports have shown that concomitant inhibition of EGFR and MET can be clinically effective in patients with non–small cell lung cancer carrying EGFR mutations and MET amplifi cation, but large phase III trials in genetically unselected individuals have failed to confi rm the benefi t of this combination therapy. A new study corroborates the evidence that lung cancer susceptibility to EGFR and MET blockade is sustained by genetically based activation of both targets and identifi es a mutation in MET that confers acquired resistance to standard MET inhibitors hitting the active kinase, yet is vulnerable to other MET-directed compounds with a different binding mode.
Original languageEnglish
JournalCancer Discovery
Publication statusPublished - 2016

Fingerprint Dive into the research topics of 'Oncogenic MET as an Effective Therapeutic Target in Non–Small Cell Lung Cancer Resistant to EGFR Inhibitors: The Rise of the Phoenix'. Together they form a unique fingerprint.

  • Cite this